SLC6A8 is called a creatine transporter, and RGX-202, a therapeutic agent that inhibits SLC6A8, inhibits the progression of colorectal cancer metastasis, indicating that creatine metabolism may be a therapeutic target [91]. The gene discussed is SLC6A8; the disease is colorectal cancer.